PTEN deletion	Gastric Cancer	PTEN deletion	Gastric Cancer	AZD8186 Sensitive: C2 – Inclusion Criteria AZD8186 Sensitive : C2	AZD8186 Sensitive: C2 – Inclusion Criteria AZD8186 Sensitive : C2
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PTEN mutation	Melanoma	PTEN mutation	Melanoma	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3
HLA-A*02	Gastric Cancer	HLA-A*02	Gastric Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PIK3R1 M326I	Gastric Cancer	PIK3R1 M326I	Gastric Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3
PIK3CB mutation	Gastric Cancer	PIK3CB mutation	Gastric Cancer	AZD8186 Sensitive: C3 – Early Trials AZD8186 Sensitive : C3	AZD8186 Sensitive: C3 – Early Trials AZD8186 Sensitive : C3
PTEN deletion	Triple Negative Breast Cancer	PTEN deletion	Triple Negative Breast Cancer	AZD8186 Sensitive: D – Preclinical AZD8186 Sensitive : D	AZD8186 Sensitive: D – Preclinical AZD8186 Sensitive : D
PTEN deletion	Melanoma	PTEN deletion	Melanoma	GSK2636771 + ENUM004 Sensitive: D – Preclinical GSK2636771 + ENUM004 Sensitive : D	GSK2636771 + ENUM004 Sensitive: D – Preclinical GSK2636771 + ENUM004 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	AZD6482 Resistant: D – Preclinical AZD6482 Resistant : D	AZD6482 Resistant: D – Preclinical AZD6482 Resistant : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	A66 + AZD6482 Sensitive: D – Preclinical A66 + AZD6482 Sensitive : D	A66 + AZD6482 Sensitive: D – Preclinical A66 + AZD6482 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GSK2636771 + A66 Sensitive: D – Preclinical GSK2636771 + A66 Sensitive : D	GSK2636771 + A66 Sensitive: D – Preclinical GSK2636771 + A66 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	TGX-221 Sensitive: D – Preclinical TGX-221 Sensitive : D	TGX-221 Sensitive: D – Preclinical TGX-221 Sensitive : D
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D	SCH772984 + AZD8186 Sensitive: D – Preclinical SCH772984 + AZD8186 Sensitive : D

PI3Kβ inhibitor

PI3Kβ inhibitor

Associations(15)

Associations
(15)